Last reviewed · How we verify
nivolumab plus relatlimab
Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses.
Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses. Used for Malignant pleural mesothelioma.
At a glance
| Generic name | nivolumab plus relatlimab |
|---|---|
| Also known as | Opdualag® |
| Sponsor | Immatics US, Inc. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1, LAG-3 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nivolumab is a monoclonal antibody that blocks PD-1, preventing cancer cells from evading immune detection. Relatlimab is a monoclonal antibody that targets LAG-3, another immune checkpoint protein. By combining these two agents, the treatment aims to stimulate a more robust and sustained anti-tumor immune response.
Approved indications
- Malignant pleural mesothelioma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Hypothyroidism
- Hyperthyroidism
- Hypertension
- Hypophosphatemia
- Hypokalemia
- Anemia
Key clinical trials
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (PHASE1, PHASE2)
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (PHASE2, PHASE3)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nivolumab plus relatlimab CI brief — competitive landscape report
- nivolumab plus relatlimab updates RSS · CI watch RSS
- Immatics US, Inc. portfolio CI